Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort
A new CAR-T therapy targeting two protein markers simultaneously addresses why some children relapse after standard single-target treatments.
This named-patient cohort reports on CART22.19 — a dual-antigen chimeric antigen receptor T-cell therapy simultaneously targeting CD22 and CD19 — in refractory pediatric B-cell ALL at a German academic center. Dual targeting addresses the common mechanism of CD19 antigen escape that limits single-target CD19 CAR-T therapies, providing a rationale for next-generation CAR-T design in pediatric ALL.
What the study was
- Study design
- Named-patient cohort (compassionate use case series)
- Population
- Refractory pediatric B-ALL patients who received named-patient access
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
Dual CD22+CD19 CAR-T addresses CD19 antigen escape, a key resistance mechanism in B-ALL; high unmet need in refractory pediatric ALL; J Immunother Cancer (high-impact journal); NOVEL_TREATMENT flag triggers HIGH classification despite named-patient design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.